Certara, Inc. $CERT Shares Sold by Wasatch Advisors LP

Wasatch Advisors LP reduced its position in shares of Certara, Inc. (NASDAQ:CERT) by 69.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,272,166 shares of the company’s stock after selling 11,950,915 shares during the period. Wasatch Advisors LP’s holdings in Certara were worth $30,051,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in shares of Certara by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 8,387,484 shares of the company’s stock valued at $73,894,000 after acquiring an additional 35,203 shares in the last quarter. Deerfield Management Company L.P. increased its position in shares of Certara by 71.7% during the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after purchasing an additional 2,813,438 shares in the last quarter. Geneva Capital Management LLC raised its stake in Certara by 0.7% in the 3rd quarter. Geneva Capital Management LLC now owns 6,160,754 shares of the company’s stock valued at $75,284,000 after purchasing an additional 45,859 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Certara by 27.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after purchasing an additional 1,165,064 shares during the last quarter. Finally, State Street Corp lifted its holdings in Certara by 2.2% in the 4th quarter. State Street Corp now owns 3,918,784 shares of the company’s stock valued at $34,524,000 after purchasing an additional 83,698 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Craig Hallum lowered their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. KeyCorp decreased their price target on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. Barclays dropped their price objective on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Finally, BMO Capital Markets decreased their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.85.

Certara Stock Up 6.1%

Shares of NASDAQ:CERT opened at $5.83 on Friday. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The business has a fifty day moving average of $5.58 and a two-hundred day moving average of $6.93. The stock has a market cap of $906.17 million, a P/E ratio of -58.25 and a beta of 1.49. Certara, Inc. has a 52-week low of $4.45 and a 52-week high of $13.88.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The company had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. During the same period last year, the business earned $0.14 earnings per share. The firm’s revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, research analysts expect that Certara, Inc. will post 0.24 earnings per share for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.